Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 3, 2011, Pages 443-449

  Strain, E C ^a   Harrison, J A ^a   Bigelow, G E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; COCAINE; DIAMORPHINE; MORPHINE; NALOXONE; NICOTINE; OPIATE;

ADULT; ARTICLE; BIOFILM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WITHDRAWAL SYNDROME;

ADMINISTRATION, SUBLINGUAL; ADULT; BUPRENORPHINE; DOUBLE-BLIND METHOD; DRUG APPROVAL; DRUG PACKAGING; FEMALE; HUMANS; MALE; MEDICATION SYSTEMS; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SOLUBILITY; SUBSTANCE WITHDRAWAL SYNDROME; TABLETS; TASTE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79951810178     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.352     Document Type: Article

References (22)

1. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-34, DHHS Publication no. SMA 08-4343; Rockville, MD, 2008).
2. Mark, T.L., Woody, G.E., Juday, T. & Kleber, H.D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 61, 195-206 (2001).
3. Jasinski, D.R., Pevnick, J.S. & Griffith, J.D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch. Gen. Psychiatry 35, 501-516 (1978).
4. Ling, W. Buprenorphine for opioid dependence. Expert Rev. Neurother. 9, 609-616 (2009).
5. Jones, H.E. Practical considerations for the clinical use of buprenorphine. Sci. Pract. Perspect. 2, 4-20 (2004).
6. Strain, E.C., Stoller, K., Walsh, S.L. & Bigelow, G.E. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl.) 148, 374-383 (2000).
7. Boyer, E.W., McCance-Katz, E.F. & Marcus, S. Methadone and buprenorphine toxicity in children. Am. J. Addict. 19, 89-95 (2010).
8. Das, N.G. & Das, S.K. Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery. Drug Deliv. 11, 89-95 (2004).
9. Rosado, J., Walsh, S.L., Bigelow, G.E. & Strain, E.C. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 90, 261-269 (2007).
10. Strain, E.C., Preston, K.L., Liebson, I.A. & Bigelow, G.E. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J. Pharmacol. Exp. Ther. 272, 628-638 (1995).
11. Tompkins, D.A., Bigelow, G.E., Harrison, J.A., Johnson, R.E., Fudala, P.J. & Strain, E.C. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 105, 154-159 (2009).
12. Petry, N.M., Bickel, W.K., Piasecki, D., Marsch, L.A. & Badger, G.J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am. J. Addict. 9, 265-269 (2000).
13. Johnson, R.E., Eissenberg, T., Stitzer, M.L., Strain, E.C., Liebson, I.A. & Bigelow, G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40, 17-25 (1995).
14. Umbricht, A., Hoover, D.R., Tucker, M.J., Leslie, J.M., Chaisson, R.E. & Preston, K.L. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend. 69, 263-272 (2003).
15. Blondell, R.D., Smith, S.J., Servoss, T.J., DeVaul, S.K. & Simons, R.L. Buprenorphine and methadone: a comparison of patient completion rates during inpatient detoxification. J. Addict. Dis. 26, 3-11 (2007).
16. Bickel, W.K., Stitzer, M.L., Bigelow, G.E., Liebson, I.A., Jasinski, D.R. & Johnson, R.E. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther. 43, 72-78 (1988).
17. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (Treatment Improvement Protocol (TIP) Series 40, DHHS Publication no. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration, Rockville, MD, 2004).
18. Spitzer, R., Williams, J. Structured Interview for DSM-III-R (SCID) (New York State Psychiatric Institute, Biometrics Research, New York, 1987).
19. Folstein, M.F., Folstein, S.E. & McHugh, P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198 (1975).
20. Wesson, D.R. & Ling, W. The Clinical Opiate Withdrawal Scale (COWS). J. Psychoactive Drugs 35, 253-259 (2003).
21. Peachey, J.E. & Lei, H. Assessment of opioid dependence with naloxone. Br. J. Addict. 83, 193-201 (1988).
22. Stout, R.L., Wirtz, P.W., Carbonari, J.P. & Del Boca, F.K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J. Stud. Alcohol. Suppl. 12, 70-75 (1994).